McGill University

Phase	Trial [desc]	Trial Status	Site Status	Drug	NCT#
1/2	Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors	Completed	Closed	EDO-S101	NCT03345485
3	A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy (StrateGIST 3)	Recruiting	Active	IDRX-42	NCT07218926
3	A Phase 3 Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (INSIGHT)	Active, not recruiting	Closed	Ripretinib	NCT05734105